|
| Status |
Public on Feb 04, 2022 |
| Title |
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
Expression profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
35338135 |
| |
| Submission date |
Oct 19, 2020 |
| Last update date |
Apr 27, 2022 |
| Contact name |
Julia Joung |
| E-mail(s) |
julia@joung.science
|
| Organization name |
Broad Institute
|
| Street address |
75 Ames St
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02142 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (37)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE159538 |
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity |
| GSE159539 |
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity |
| GSE197309 |
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity (sgRNA distribution) |
|
| Relations |
| BioProject |
PRJNA669676 |
Less...
More...